How to Buy Cullinan Therapeutics, Inc. Common Stock (CGEM) Stock

Where to buy CGEM

13 brokers in our matrix offer CGEM. Verify availability and current fees with each broker before trading.

Broker	Commission	Fractional	Extended	Overnight	Options	OTC access
Charles Schwab (thinkorswim)Review	$0	Schwab Stock Slices, S&P 500 only, ≥ $5/slice, up to 30 at once		~1,130	$0.65	Most (3/5)
E*TRADE (Morgan Stanley)Review	$0 listed			~20	$0.65	Most (4/5)
FidelityReview	$0	Stocks by the Slice, 7,000+ stocks/ETFs, from $1			$0.65	Partial (2+0)
FirstradeReview	$0	~4,000+ tickers, ≥ $5		~1,200	$0	Most (4/5)
Interactive BrokersReview	$0 (Lite) / per-share (Pro)			~10,000	per-contract pricing	Full
Merrill EdgeReview	$0				$0.65	Most (3/5)
MoomooReview	$0				$0	Limited only
Public.comReview	$0				rebate model	Limited only
RobinhoodReview	$0	≥ $1 stocks, market cap ≥ $25M		~1,134	$0	None
SoFi Active InvestingReview	$0				$0	Partial (1+2)
tastytradeReview	$0 stocks				$1.00 open, $0 close (capped at $10 per leg)	Limited only
TradeStationReview	$0 listed				$0.50 / $0.60	Most (4/5)
WebullReview	$0				$0	Limited only

24-Hour / Overnight trading

CGEM may be eligible for overnight trading via Charles Schwab (thinkorswim), Interactive Brokers, Robinhood, E*TRADE (Morgan Stanley), Webull, Moomoo, Firstrade. Each broker maintains its own eligibility list — confirm before placing an order.

About Cullinan Therapeutics, Inc. Common Stock

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Employees

109

Headquarters

CAMBRIDGE, MA

Listed

2021-01-08

Market cap

$880.69M

Frequently asked

Where can I buy Cullinan Therapeutics, Inc. Common Stock (CGEM)?

CGEM is offered by 13 brokers in our matrix, including Charles Schwab (thinkorswim), E*TRADE (Morgan Stanley), Fidelity, Firstrade, Interactive Brokers. Compare commissions, fractional eligibility, and overnight availability in the broker matrix above.

Can I buy CGEM after hours or overnight?

Yes. CGEM is on the 24-hour eligibility list for Charles Schwab (thinkorswim), Interactive Brokers, Robinhood, E*TRADE (Morgan Stanley), and others. Overnight sessions route through ATSs with wider spreads and limit-orders only.

Does Robinhood offer CGEM?

Yes. Robinhood offers CGEM as a regular exchange-listed security.

Does Fidelity offer CGEM?

Yes. Fidelity offers CGEM as a regular exchange-listed security.

Does Webull offer CGEM?

Yes. Webull offers CGEM as a regular exchange-listed security.

Is CGEM optionable?

Yes. CGEM has listed options contracts. Per-contract pricing varies by broker — see the Options column in the matrix.

Is there a tokenized version of CGEM?

Not in our current dataset. The tokenized stock universe (Kraken xStocks, Binance Alpha/Ondo, Robinhood EU, Hyperliquid HIP-3) is expanding quickly — we refresh quarterly.

Can I buy a fractional share of CGEM?

Yes. Multiple brokers in the matrix support fractional shares for CGEM — see the Fractional column above for per-broker eligibility and minimums.